Director, Hematology Oncology Division
Mary Gilbreth Professor of Clinical Oncology

Dr. Drabkin received his M.D. degree from the University of Kansas, completed his internship and residency in Internal Medicine at the University of Cincinnati, and was a Fellow in Hematology-Oncology at the University of Colorado. While at Colorado, Dr. Drabkin rose through the ranks to become full Professor in 1998 and received the Grohne-Stapp Chair in Cancer Research in 2006.

Dr. Drabkin has made major contributions to our understanding of the pathogenesis of malignant diseases, particular in the areas of leukemia, kidney cancer and lung cancer. Among his accomplishments are the discovery of the AML1-ETO fusion transcript that results from the 8;21 translocation in AML, the discovery of the hereditary kidney cancer gene, TRC8, and its function, and the identification of the tumor suppressor gene, SEMA3F and its role in lung cancer. Clinically, Dr. Drabkin is known for the treatment of metastatic kidney cancer and is active in Cooperative Group, Industry, and Investigator-initiated trials in this disease. He is the author of ~150 peer-reviewed articles and book chapters.

Dr. Drabkin joined MUSC as Chief of Hematology-Oncology in May, 2007. In addition to his role as Division Chief, Dr. Drabkin will maintain his effort in basic and translational research. Clinically, Dr. Drabkin’s goal is to establish a Center of Excellence in metastatic kidney cancer providing state-of-the-art clinical trials, new agents and new combinations to patients with this disease in South Carolina and the region.

 Dr. Drabkin's Curriculum Vitae (PDF Format)*

* Note in order to view this document you will need to have the free Adobe Reader  installed on your computer. More on Adobe Acrobat.

  More on Dr. Drabkin